Cargando…

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis

We assessed safety and tolerability of treatment with pirfenidone (1602–2403 mg·day(−1)) and nintedanib (200–300 mg·day(−1)) in patients with idiopathic pulmonary fibrosis (IPF). This 24-week, single-arm, open-label, phase IV study (ClinicalTrials.gov identifier NCT02598193) enrolled patients with I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flaherty, Kevin R., Fell, Charlene D., Huggins, J. Terrill, Nunes, Hilario, Sussman, Robert, Valenzuela, Claudia, Petzinger, Ute, Stauffer, John L., Gilberg, Frank, Bengus, Monica, Wijsenbeek, Marlies
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092682/ https://www.ncbi.nlm.nih.gov/pubmed/29946005 http://dx.doi.org/10.1183/13993003.00230-2018

Ejemplares similares

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
por: Moor, C. C., et al.
Publicado: (2020)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
por: Belhassen, Manon, et al.
Publicado: (2021)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
por: Rinciog, C., et al.
Publicado: (2020)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe
por: Kaushal, Mohit, et al.
Publicado: (2022)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
por: Takehara, Kazutaka, et al.
Publicado: (2022)

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
por: Holtze, Colin H., et al.
Publicado: (2020)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
por: Marijic, Pavo, et al.
Publicado: (2021)

Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine
por: Myllärniemi, Marjukka, et al.
Publicado: (2015)

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
por: Hughes, Gareth, et al.
Publicado: (2016)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
por: Serra López-Matencio, José M., et al.
Publicado: (2021)

Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone
por: Ipatova, Anastasia Y, et al.
Publicado: (2019)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data
por: Khan, Mohammed Ayaz, et al.
Publicado: (2023)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
por: Amati, Francesco, et al.
Publicado: (2023)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
por: Fois, Alessandro G., et al.
Publicado: (2020)

Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
por: Roach, KM, et al.
Publicado: (2021)

Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study
por: Wijsenbeek, Marlies, et al.
Publicado: (2018)

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis
por: Ikeda, Satoshi, et al.
Publicado: (2019)

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
por: Cameli, Paolo, et al.
Publicado: (2020)

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
por: Bonella, Francesco, et al.
Publicado: (2022)

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
por: Nathan, Steven D, et al.
Publicado: (2018)

Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study
por: Vianello, Andrea, et al.
Publicado: (2020)

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis
por: Wijsenbeek, Marlies S., et al.
Publicado: (2015)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Effectiveness and Safety of Pirfenidone and Nintedanib for Pulmonary Fibrosis in COVID-19-Induced Severe Pneumonia: An Interventional Study
por: Choudhary, Rajkamal, et al.
Publicado: (2022)

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
por: Molina-Molina, Maria, et al.
Publicado: (2023)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
por: Noth, Imre, et al.
Publicado: (2019)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
por: Chu, Kuo-An, et al.
Publicado: (2020)

Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study
por: Miedema, Jelle R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_so0i0o829bc933f77pllaphv6g